

CLAIMS

1. A mutated CD200 protein comprising a mutation at amino acid residue position 130 and/or 131 corresponding to SEQ ID NO: 1, wherein said mutation is a substitution mutation selected from K130Y and/or I131Y, wherein the protein is an agonist of the CD200 receptor.
2. The protein as defined in claim 1, which comprises one or more additional mutations, such as those selected from G129I, F128R, and N81K.
3. The protein as defined in claim 2, comprising the sequence of SEQ ID NO: 12 or SEQ ID NO: 13.
4. The protein as defined in any one of claims 1 to 3, which comprises the extracellular domain (ECD) of said protein.
5. The protein as defined in any of claims 1 to 4, comprising the sequence of SEQ ID NO: 3 or SEQ ID NO: 4.
6. A fusion protein comprising the protein as defined in any of claims 1 to 5, fused to a non-CD200 protein encoding portion via an optional linker portion.
7. The protein as defined in claim 6, wherein said linker portion is a peptide comprising between 1 and 15 amino acids.
8. The protein as defined in claim 6 or claim 7, wherein said non-CD200 protein encoding portion is an antibody or fragment thereof.
9. The protein as defined in any of claims 6 to 8, wherein said non-CD200 protein encoding portion is an Fc fragment.
10. The protein as defined in any of claims 6 to 9, comprising the sequence of SEQ ID NO: 6 or SEQ ID NO: 7.

11. A polynucleotide encoding a protein as defined in any of claims 1 to 10.

12. A pharmaceutical composition comprising the protein as defined in any of claims 1 to 10.

5

13. Use of the protein as defined in any of claims 1 to 10, or the composition as defined in claim 12 in the manufacture of a medicament for the treatment of autoimmune disease.